Recently it has been demonstrated that overexpression of NRF2 and its target genes in a Gefitinib-resistant non-small cell lung cancer cell line can be attributed to an acquired Keap1 mutation. This evidence concerns the gene NFE2L2 and non-small cell lung carcinoma.